TrialStem cell research & therapy2025

Long-term outcomes of mesenchymal stem cell therapy in severe COVID-19 patients: 3-year follow-up of a randomized, double-blind, placebo-controlled trial.

Meng-Qi Yuan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.